On November 5, MICO Pharmaceutical (688373) issued an announcement stating that the company recently received the "Approval Notice for Supplementary Application for Drug" and the "Approval Notice for Supplementary Application for Drug Clinical Trial" issued by the National Medical Products Administration.
The announcement stated that Jiangsu Xuantai Pharmaceutical Co., Ltd. has been approved as a new contract manufacturer for continazolamide tablets, while Chongqing Boteng Pharmaceutical Technology Co., Ltd. will serve as its active pharmaceutical ingredient supplier. Continazolamide tablets are a new generation of oxazolidinone antibacterial drug used to treat complicated skin and soft tissue infections. The product was approved for marketing in China in June 2021.
In addition, the announcement also mentioned that the supplemental application for clinical trials of MRX-5 tablets has been approved, allowing for the addition of a 200mg dosage for clinical trials. MRX-5 is a novel benzoborazole antibiotic intended for the treatment of infections caused by nontuberculous mycobacteria. The drug has demonstrated favorable safety and pharmacokinetic properties in animal and human studies, and has completed Phase I clinical trials in Australia, and has received orphan drug designation from the U.S. Food and Drug Administration.
In the first three quarters of 2025, Mengke Pharmaceutical achieved revenue of 104 million yuan and net profit attributable to the parent company of -194 million yuan.

https://finance.eastmoney.com/a/202511053555928363.html